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Abstract
Background: Prostaglandin E2 (PGE2), experimentally administered to asthma patients or assayed
in murine models, improves allergen-driven airway inflammation. The mechanisms are unknown,
but fluctuations of the endogenous cyclooxygenase (COX)-2/prostaglandin/E prostanoid (EP)
receptor pathway activity likely contribute to the clinical outcome. We analyzed the activity of the
pathway in mice sensitized to aeroallergens, and then studied its modulation under exogenous
PGE2.
Methods: Mice were exposed to house dust mite (HDM) aeroallergens, a model that enable us to
mimic the development of allergic asthma in humans, and were then treated with either
subcutaneous PGE2 or the selective EP1/3 receptor agonist sulprostone. Simultaneously with
airway responsiveness and inflammation, lung COX-2 and EP receptor mRNA expression were
assessed. Levels of PGE2, PGI2, PGD2 were also determined in bronchoalveolar lavage fluid.
Results: HDM-induced airway hyperreactivity and inflammation were accompanied by increased
COX-2 mRNA production. In parallel, airway PGE2 and PGI2, but not PGD2, were upregulated, and
the EP2 receptor showed overexpression. Subcutaneous PGE2 attenuated aeroallergen-driven
airway eosinophilic inflammation and reduced endogenous PGE2 and PGI2 production. Sulprostone
had neither an effect on airway responsiveness or inflammation nor diminished allergen-induced
COX-2 and PGE2 overexpression. Finally, lung EP2 receptor levels remained high in mice treated
with PGE2, but not in those treated with sulprostone.
Conclusion: The lung COX-2/PGE2/EP2 receptor pathway is upregulated in HDM-exposed mice,
possibly as an effort to attenuate allergen-induced airway inflammation. Exogenous PGE2
downregulates its endogenous counterpart but maintains EP2 overexpression, a phenomenon that
might be required for administered PGE2 to exert its protective effect.
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Background
Allergic asthma is a common inflammatory disease of the
airway, and long-term therapy is aimed at counteracting
episodes of bronchospasm and reducing allergic inflam-
mation. Although such strategies are successful, they nei-
ther cure nor prevent asthma, and, in some cases, have not
prevented the disease from progressing [1]. Therefore,
new therapeutic strategies must be identified [2]. Studies
in mice models of asthma have shed light on the patho-
physiology of the disease, and they have enabled us to
hypothesize about novel targets for treatment [3,4]. The
protective nature of endogenous molecules such as pros-
taglandin (PG) E2 provides us with an unusual opportu-
nity to develop research projects aimed at uncovering
novel targets. Interest in PGE2 as a clinically beneficial
agent in asthma and asthma-like syndromes [5,6] has
been rekindled in pre-clinical settings, and has encour-
aged investigators to further analyze the underlying mech-
anisms in vitro and in vivo [7-9]. The roles of endogenous
PGE2  and of fluctuations in cyclooxygenase (COX)-2
activity in modulating airway reactivity and bronchial
inflammation have been investigated in experimental
rodent models of asthma by various groups [10,11],
including ours [12,13]. In addition, we recently reported
an improvement in airway inflammation after adminis-
tration of subcutaneous PGE2  in the murine airway
response to house dust mite (HDM) aeroallergens [14].
Our study reproduced observations in humans [5,6] and
some of the very recently published data from ovalbumin
(OVA)-sensitized mice [7]. Although little is known about
the mechanisms involved, our work has also pointed to a
PGE2-induced restraining effect on airway mast cell activ-
ity as a potentially relevant mediating phenomenon
[13,14]. These in vivo data build on the results of in vitro
experiments in which anti-inflammatory and immuno-
suppressive actions of PGE2 had been reported. PGE2 has
been shown to exert an inhibitory effect on the activity of
mast cells [8,15] and to suppress immunological mecha-
nisms such as dendritic [16], and T [17] cell activation.
The findings of our and other groups point to a protective
effect of PGE2 involving several stages of asthma progres-
sion. A recurrent finding is the effect of PGE2 on cellular
COX expression in vitro [18-20]. This is an area of interest,
since the external provision of an endogenous molecule
such as a PG might also affect in vivo the balance of the
internal system of COX-2-PGE2-EP, and such an effect on
the endogenous COX pathway possibly contributes to the
clinical benefit resulting from administration of PGE2.
Similarly, the PGE2-induced fluctuation of E prostanoid
(EP) receptor (PGE2 receptor) expression shown in vitro
[21,22], may have a profound impact on the ability of
exogenous PGE2 to modulate the murine airway response
to HDM. The EP3 receptor may be a main candidate for
protection [23]. Despite its interest, the functional conse-
quences on the COX-2-PGE2-EP receptor pathway of
administering PGE2 in vivo remains largely unknown.
This gap is probably partly attributable to the lack of accu-
rate data on the fluctuating activity of the endogenous
COX system in aeroallergen-induced asthma. Therefore,
the direction, the relevance, and the implications of the
fluctuations of different elements of the COX pathway
need to be ascertained as a whole in an in vivo system.
We used HDM-sensitized mice, whose unique features
enable us to mimic the development of allergic asthma in
humans, to characterize in vivo the COX-2-PGE2-EP path-
way. Under the hypothesis that PGE2-driven changes in
airway inflammation are also attributable to fluctuations
in the internal functioning of this axis, we proceeded to
evaluate how expression of COX-2, PG, and EP were
affected by the administration of PGE2.
Methods
HDM-sensitive mice and experimental groups
Samples from mice sensitized to HDM aeroallergens that
had been shown to develop airway hyperreactivity and
inflammation [14], were used in the present study. Briefly,
eight-week-old female BALBc mice (Harlan, Spain)
housed under a 12-hour light-dark cycle, had been
exposed to a purified HDM extract (Alk-Abelló, Madrid,
Spain) with a low lipopolysaccharide (LPS) content (<0.5
EU/dose, measured using the Charles River Endosafe
Limulus Amebocyte Assay, Charles River Laboratories,
Wilmington, Massachusetts, USA). The allergen was
administered intranasally at a dose of 25 g/mouse in a
10 l volume for 10 consecutive days. Immediately before
administration of HDM, light anesthesia was induced in a
chamber filled with 4% halothane delivered over a period
of 2 minutes in 100% oxygen and maintained for 2 addi-
tional minutes with 2.5% halothane. Non-sensitized
(control) animals were handled identically, except that
they received intranasal saline instead of HDM extract.
Six experimental groups were established. The first 3
groups contained non-sensitized (control) mice: group 1
contained untreated mice (n = 15) and groups 2 and 3
contained PGE2-treated (n = 15) and sulprostone-treated
(n = 5) animals, respectively. The remaining 3 groups con-
tained HDM-sensitized mice: group 4 included untreated
animals (n = 21), and groups 5 and 6 contained PGE2-
treated (n = 21) and sulprostone-treated (n = 11) animals,
respectively. All animal procedures were approved by the
Ethics Committee for Animal Research of the Universitat
Autònoma de Barcelona.
Administration of subcutaneous PGE2 and sulprostone
Both HDM-sensitized and non-sensitized mice had been
treated with either PGE2 (0.5 mg/kg) or sulprostone (80
g/kg), an EP3 agonist with a slight EP1 effect. Both EP
receptor agonists were injected subcutaneously on theJournal of Inflammation 2009, 6:30 http://www.journal-inflammation.com/content/6/1/30
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same day as the HDM extract, although their administra-
tion was continued up to day 11 (ie, 2 days after the aller-
gen was withdrawn). The prostanoid treatment was
provided 1 hour before exposure to HDM. PGE2 was pur-
chased from Cayman (Tallinn, Estonia, ref. 14010) and
the solution was prepared daily in phosphate-buffered
saline (PBS) from a stock solution dissolved in dimethyl
sulfoxide (DMSO) and stored at -20°C. The final concen-
tration of DMSO injected was 0.1%. Sulprostone (Cay-
man, ref. 14765) was also prepared daily in PBS, and the
solution administered contained 0.05% DMSO. The
untreated mice underwent the same procedure, except
that they received subcutaneous vehicle (PBS containing
0.1% DMSO) instead of the EP agonist.
Assessment of COX-2 mRNA expression in the lungs
COX-2 mRNA expression in the lungs was assessed by real
time polymerase chain reaction (PCR). After sacrifice, the
intermediate lung lobe was kept at -80°C for RNA extrac-
tion. Total RNA was extracted using Trireagent (Molecular
Research Center Inc, Cincinnati, Ohio, USA), and traces of
contaminating genomic DNA were removed using DNA-
free (Ambion Inc, Austin, Texas, USA). COX-2 cDNA was
generated using MMLV reverse transcriptase (Epicentre,
Madison, Wisconsin, USA). For real time-PCR, 2 g of
total RNA from each animal was reverse-transcribed and 2
l of a 1/5 dilution of the resulting cDNA was placed into
glass capillaries together with 18 l of a master-mix. The
COX-2 primers were designed with PrimerSelect software
(DNASTAR Inc, Madison, Wisconsin, USA), and were as
follows: forward primer
5'AGCCAGCAAAGCCTAGAGCAACAA3' and reverse
primer 5'TGACCACGAGAAACGGAACTAAGAGG3'. PCR
was performed in a LightCycler Instrument and the cross-
ing point (CP, defined as the point at which fluorescence
increases appreciably above background fluorescence)
was determined by LightCycler software (both from
Roche Diagnostics, Mannheim, Germany) using the sec-
ond derivative maximum method.
Assessment of PGE2, PGI2 and PGD2 levels in BAL fluid
After sacrifice, BAL fluid was centrifuged at 400 rcf for 5
minutes at 4°C and supernatants were collected and
stored at -80°C for analysis. The endogenous production
of PGE2, 6-keto PGF1 (a metabolite of PGI2), and PGD2
was determined in BAL fluid using a commercial compet-
itive ELISA (Cayman, ref: 514010, 515211, 512021) fol-
lowing the manufacturer's instructions. Briefly, either the
standards or the samples were incubated with the tracer
antibody, the wells were then washed to remove all
unbound reagents, and the signal was developed with Ell-
man's reagent.
Assessment of mRNA expression EP1, 2, 3, and 4 receptor 
in the lungs
mRNA expression of EP receptors 1 to 4 in the lungs was
assessed by real-time PCR using TaqMan® Gene Expres-
sion Assays containing two unlabeled primers and one 6-
FAM™ dye-labeled TaqMan® MGB probe (Applied Biosys-
tems, Foster City, California, USA, ref: Mm00443097_m1,
Mm00436051_m1, Mm0.1316856_m1,
Mm00436053_m1). Total RNA extraction and contami-
nating genomic DNA elimination were performed as for
the assessment of COX-2 expression. EP1, 2, 3, and 4
cDNA was generated using MMLV reverse transcriptase
(Epicentre, Madison, Wisconsin, USA). For real time-PCR,
2  g of total RNA from each animal was reverse-tran-
scribed and 4 l of a 1/2 dilution of the resulting cDNA
was placed into a 96-well reaction plate together with 16
l of the master-mix. The real-time PCR reaction was run
on a 7900 HT Real-Time PCR System (Applied Biosys-
tems). The crossing point (CP, defined as the point at
which fluorescence increases appreciably above back-
ground fluorescence) was determined by 7900 HT Real-
Time PCR System software (Applied Biosystems) using
the second derivative maximum method.
Statistical analysis and calculations
As for the real time PCR results analysis, the Relative
Expression Software Tool (REST©) was applied to calculate
the relative expression ratio on the basis of group means
for COX-2 or EP receptors (target genes) versus the refer-
ence gene GAPDH. The calculated group ratio was tested
for significance using a statistical model known as the Pair
Wise Fixed Reallocation Randomisation Test© [24]. We
took into account the PCR efficiency calculated for the tar-
get genes (COX-2 and EP1-4) and for GAPDH, which were
very similar. As previously published [12], for purposes of
graphic representation, the target genes (COX-2 and EP1-
4) mRNA expression ratio of the untreated non-sensitized
mice was established as 1.0, and the average ratios of the
other experimental groups were re-calculated on that
basis. ELISA PG levels were compared between groups
using the t test.
Results
Fluctuation of COX-2 pathway activity in the lungs of 
HDM-sensitized mice
As shown previously, mice intranasally sensitized to HDM
developed significant airway hyperreactivity and eosi-
nophilic inflammation [14] when compared to non-sen-
sitized animals. This reaction was accompanied by
changes in the local expression of COX-2, PG, and EP
receptors, as depicted by the dark grey bars in Figures 1
through 3. All these COX-2 pathway molecules were
determined simultaneously in every single animal, and
measurements were performed 48 hours after the last
challenge with HDM. COX-2 mRNA expression in theJournal of Inflammation 2009, 6:30 http://www.journal-inflammation.com/content/6/1/30
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lungs increased 3.6 fold in mice sensitized to HDM aer-
oallergens compared with non-sensitized mice (Figure 1).
COX-2 overexpression in the airways of HDM-sensitized
animals was accompanied by a 2.4-fold increase in the
production of both PGE2 (Figure 2a) and PGI2 (Figure
2b), but not PGD2 (Figure 2c) in BAL fluid. The mRNA
expression of PGE2 receptors EP 1 to 4 was also deter-
mined in lung extracts (Figure 3). Despite higher levels of
mRNA in all four receptors in HDM-sensitized mice than
in non-sensitized mice, only EP2 showed a statistically
significant allergen-induced upregulation in HDM-sensi-
tized mice - 4.6-fold (Figure 3b).
2Effect of exogenous PGE2 on airway COX-2 and PG 
expression in HDM-sensitized and non-sensitized mice
As previously reported [14], subcutaneous PGE2, but not
sulprostone, significantly reduced HDM-induced eosi-
nophil recruitment into the airways (by approximately
40%), but had no effect on methacholine-induced airway
hyperreactivity. In these animals, the effect of exogenous
PGE2 and sulprostone on airway COX-2 activity was meas-
ured by evaluating COX-2 mRNA expression in parallel to
the BAL COX-2 products PGE2, PGI2, and PGD2. Baseline
levels of lung COX-2 mRNA in non-sensitized mice were
significantly increased under both the PGE2  (1.8-fold
increase) and the sulprostone (2.4-fold increase) treat-
ment when compared with levels in non-sensitized or
non-treated animals (Figure 1). As observed in non-
treated sensitized animals, COX-2 expression in PGE2-
and sulprostone-treated mice increased when these mice
were sensitized to HDM allergens. The magnitude of this
increase was 2.5 fold and 3.8 fold for mice under PGE2
and sulprostone, respectively.
As for airway COX-2 product synthesis, HDM-induced
enhanced endogenous PGE2 production returned to base-
line values in sensitized animals treated with exogenous
PGE2. This effect was uncovered by the significant differ-
ence in PGE2 levels in BAL between sensitized non-treated
and PGE2-treated mice (Figure 2a). However, sulprostone
did not reduce endogenous PGE2 production in HDM-
sensitized mice. Similarly, the increase in PGI2 in BAL in
HDM-sensitized mice was lower after administration of
external PGE2  (Figure 2b). Sulprostone had a similar
inhibitory effect on PGI2 production. Finally, PGD2 was
not significantly affected by treatment with either agonist
(Figure 2c).
Expression of COX-2 mRNA in the lung parenchyma as assayed by real-time PCR Figure 1
Expression of COX-2 mRNA in the lung parenchyma as assayed by real-time PCR. The relative mRNA expression 
ratio in the non-sensitized (and untreated) mice was established as 1.0. COX-2 mRNA expression in the lungs increased 3.6 
fold in HDM-sensitized (n = 11) versus non-sensitized mice (n = 5). Baseline levels of COX-2 mRNA in the lungs were higher 
in non-sensitized mice under both PGE2 (n = 5) and sulprostone (n = 5) when compared to levels in non-sensitized and non-
treated animals. COX-2 expression in PGE2 (n = 11) and sulprostone-treated mice (n = 11) increased by 2.5 and 3.8 fold, 
respectively, when the animals were exposed to HDM (*p < 0.05, **p < 0.01, ***p < 0.005).
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Endogenous prostaglandin production in the airways as assayed by ELISA in BAL fluid Figure 2
Endogenous prostaglandin production in the airways as assayed by ELISA in BAL fluid. Graph (a) shows endog-
enous PGE2 production. PGE2 increased 2.4 fold in allergen-sensitized (n = 11) versus non-sensitized mice (n = 5). Endogenous 
PGE2 production fell significantly to baseline levels in HDM-sensitized mice treated with PGE2 (n = 11), but remained 
unchanged when mice were treated with sulprostone (n = 11). Graph (b) depicts endogenous airway 6-keto PGF1 production 
(a metabolite of PGI2). In the same way as PGE2, 6-keto PGF1 increased 2.4 fold in allergen-sensitized (n = 11) versus non-
sensitized mice (n = 5). 6-keto PGF1 production fell in HDM-sensitized mice treated with PGE2 (n = 11) and sulprostone had 
a similar inhibitory effect on BAL 6-keto PGF1 expression (n = 11). Graph (c) shows endogenous PGD2 production. No differ-
ences were found in BAL fluid levels of PGD2 in mice between any of the experimental groups (*p < 0.05, **p < 0.01, ***p < 
0.005).
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Effect of exogenous PGE2 on EP receptor expression in the 
lungs of HDM-sensitized mice
Figure 3a, b, c, and 3d depict the effect of PGE2 and sul-
prostone on lung EP receptors 1, 2, 3, and 4 mRNA expres-
sion, respectively. Treatment with either agonist did not
significantly alter the level of expression of lung EP1, 3, or
4 in either baseline (non-sensitized) or HDM-sensitized
mice from a statistical perspective. However, as for HDM-
induced EP2 overexpression in sensitized mice, sulpros-
tone, but not PGE2, prevented upregulation at 2 different
levels: it induced a 3.5-fold increase in the baseline expres-
sion of EP2, and it prevented HDM from further enhanc-
ing this baseline level.
Discussion
We have shown that, in addition to inducing airway
hyperreactivity and eosinophil recruitment, intranasal
exposure to HDM alters the endogenous COX-2 pathway
at various levels: it upregulates COX-2, PGE2, and PGI2 in
the lungs, and it enhances local EP2 receptor expression.
Exogenous PGE2 modulates these HDM-induced changes
in the COX2/PG/EP receptor pathway. Notably, in addi-
tion to reducing airway eosinophilia, it prevents HDM-
induced lung PGE2 and I2 overexpression, but does not
counteract HDM aeroallergens-induced EP2 upregulation.
Lung COX-2 mRNA expression and generation of its prod-
uct PGE2, are increased in HDM-sensitized mice. Interest-
ingly, a similar pattern is observed with PGI2, another
Relative expression of EP 1, 2, 3 and 4 receptors mRNA in lung tissue assayed by real-time PCR Figure 3
Relative expression of EP 1, 2, 3 and 4 receptors mRNA in lung tissue assayed by real-time PCR. Graphs a, b, c, 
and d show the mRNA expression of the EP1, EP2, EP3, and EP4 receptors, respectively, in the different treatment groups. EP 
receptor mRNA expression was higher for all four receptors in HDM-sensitized mice (n = 11) than in non-sensitized animals (n 
= 5), but only EP2 showed a significant allergen-induced upregulation (4.6 fold). Treatment with either agonist (PGE2 or sul-
prostone) did not significantly alter the level of expression of lung EP1, 3, and 4 in non-sensitized (n = 5) or HDM-sensitized 
mice (n = 11). However, sulprostone, but not PGE2, induced a 3.5-fold increased expression of EP2 baseline levels (non-sensi-
tized mice), and it then prevented HDM from further enhancing these levels (*p < 0.05, **p < 0.01).
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anti-inflammatory PG [25], but not with PGD2. We know
that COX-2 upregulation is tightly linked to PGE synthase
(PGES-1) activity [26]. In turn, although PGI2 was tradi-
tionally considered to derive mainly from COX-1, in the
last few years this paradigm has proven to be incorrect,
since studies in mice and humans have shown that COX-
2 is the dominant source of PGI2 [26]. The fluctuations of
PGE2  and PGI2  are therefore possibly the result of
enhanced expression of COX-2. As far as we know, ours is
the first report to demonstrate aeroallergen-induced mod-
ulation of the complete COX-2 pathway. This builds on
our previous results [12], in which we detected a trend
towards increased COX-2 and PGE2 activity in the lungs of
HDM-sensitized mice, and on an earlier report in which
OVA-sensitized guinea pigs were used [27]. It is difficult to
uncover the significance of aeroallergen-induced
increased lung COX-2 production. According to our and
others hypothesis, asthma develops partly as a result of
improper regulation of COX-2 activity [28,29], and, given
that PGE2 and PGI2 are considered anti-inflammatory pro-
tective prostanoids within the lungs [25,30], we speculate
that PGE2 and PGI2, but not PGD2, attempt to trigger a
beneficial compensatory phenomenon in mice exposed to
HDM. Although this concept has yet to be proven, our in
vivo data confirm in vitro findings where the overactivity
of the COX-2/PGE2/EP2 pathway was viewed as an effort
to minimize allergen-induced damage [18,31]. This idea
is reinforced by the fact that airway pathology worsens
when endogenous PGE2 is presumably inhibited either
genetically or pharmacologically in antigen-sensitized
mice, as shown by ours [13] and other groups [10,11].
PGD2, in turn, has traditionally been described as a PG
inducing functional exacerbation of the airways, despite
the fact that recent articles report a potentially beneficial
effect [32,33]. In our view, the unchanged levels of PGD2
in our setting two days after the last allergen challenge
could be attributable to timing issues, i.e. PGD2 probably
peaks immediately after challenge. If so, a different exper-
imental time-course approach would be required to reveal
such PGD2 fluctuations in the HDM mouse model.
Data on whether COX-2, PGE2 and/or PGI2 are overpro-
duced or not in the lungs of asthmatics are contradictory.
Several authors have described either upregulation, or
downregulation and even unchanged levels [28,29,34-
37]. These contradictions could timing-related [38] or be
genetically determined; in any case, they reflect the com-
plexity of understanding COX-2/PG dynamics in the
lungs of asthmatics and confirm the need for an experi-
mental in vivo approach to identify the actual changes
and their clinical impact. The genetic basis is a fundamen-
tal issue, since it has been hypothesized that the COX-2
gene might be altered in asthmatics [28,29,38]. This
potential human genetic defect does not affect mice and
this probably explains why in our study the animals
remain fully able to respond with consistent COX-2 activ-
ity increases when exposed to aeroallergens.
In addition to COX-2 and PGE2, intranasal HDM selec-
tively increases EP2 receptor expression in the lungs of
mice. It is worth noting that increases in mRNA levels
were detected in all four receptors, but that statistical sig-
nificance was only reached with EP2. The lack of statistical
significance in EP1, 3 and 4 is probably attributable to
interindividual variability of endogenous molecules
expression and to the nature of the mRNA detection sys-
tem. Despite such technical limitations, EP2 overexpres-
sion was shown to be consistent and statistically
significant. This would suggest that EP2 uregulation is a
relevant trait of an internal defensive strategy of the COX-
2/PGE2/EP pathway against HDM aeroallergens aggres-
sion, but such statement requires further experimental
evidence. Our hypothesis on a leading anti-inflammatory
role of EP2 in HDM-sensitive mice would agree with find-
ings from in vitro experimental approaches where EP2
was proposed a candidate receptor to mediate the benefi-
cial effects of PGE2 in humans [7,8,15]. Although not
reported from in vivo experiments in mice models, a
selective upregulation of EP2 has been described by Bur-
gess JK et al. [31] in airway smooth muscle cells from asth-
matics. All in all, an internal EP2-mediated compensatory
mechanism aimed at reducing the damage induced by
HDM in animals whose COX-2/PG armamentarium is
genetically intact seems to be a reasonable explanation. In
order to ascertain the relevance of a selective EP2 increase
in attenuating airway pathology, EP2 receptor genetic
manipulation (e.g. antisense oligonucleotide or iRNA)
would be required.
A recent report by our group [14] showed that PGE2 signif-
icantly reduced to almost a half HDM-induced airway
eosinophilia, but had no effect on AHR. An intensive sin-
gle-dose treatment protocol with the agonists starting a
day before the actual exposure to HDM was used with the
purpose of ensuring that effective prostanoid levels would
be present during the relevant phases of the process,
regardless of the clinical relevance of such concentrations.
The early treatment with the EP agonists was also partly
based on the reported immuosuppressive effects of PGE2
in vitro [16,17]. We have now observed that, under this
protocol, in parallel to preventing eosinophil recruitment,
exogenous PGE2 clearly attenuates endogenous produc-
tion of PGE2 and PGI2. Lung COX-2 expression, if at all, is
only very slightly affected and certainly not to the extent
of the change in PG production. A straightforward expla-
nation would be that exogenous PGE2 overtakes the role
exerted by the endogenous PG, with no need to maintain
a similar endogenous production of PGE2 and PGI2, since
an external source of PGE2 is already provided. This wouldJournal of Inflammation 2009, 6:30 http://www.journal-inflammation.com/content/6/1/30
Page 8 of 9
(page number not for citation purposes)
therefore be viewed as a classical negative feedback mech-
anism, possibly on the PG synthases rather than COX-2.
Alternatively, the reduced PG expression in the presence
of exogenous PGE2 might be the result of less infiltrated
inflammatory cells producing such PG within the airways.
Sulprostone neither reduces inflammation nor alters the
HDM-induced increase in COX-2 or PGE2 levels. It does
exert some effect on the level of COX-2 mRNA expression,
although such an effect is similar in HDM-sensitized and
non-sensitized animals. Therefore, this phenomenon
does not selectively occur in allergen-sensitized mice. This
somehow shows that EP1/EP3 and EP2 (and possibly
EP4) are independent systems, and confirms that PGE2
anti-inflammatory activity in HDM aeroallergens-induced
airway pathology in mice is more likely the result of an
EP2-mediated effect as discussed earlier. To confirm this
hypothesis further experiments with an EP2 selective ago-
nist are required. Interestingly, the analysis of airway EP
receptor expression in the presence of EP receptor agonists
brings us to a similar conclusion. Exogenous PGE2 does
not prevent the HDM-induced increase in EP2, but sul-
prostone does. Given the observed anti-inflammatory
nature of PGE2 (but not sulprostone) [14], this supports
the assertion that the increase in EP2 is necessary in medi-
ating the anti-inflammatory effect of PGE2. Furthermore,
our data suggest that an EP2 agonist, whether exogenous
or endogenous, is needed to keep EP2 levels raised.
Finally, it is noteworthy that lung levels of EP2 are similar
in HMD-sensitized mice regardless whether they are
treated or not with PGE2, and yet PGE2-treated mice do
have lower numbers of eosinophils in the airways [14].
This suggests that exogenously delivered PGE2  peaks
(undetected by ELISA) are necessary for protection simul-
taneously to the overexpression of EP2.
Conclusion
In summary, we can infer that exposure to HDM aeroaller-
gens in mice boosts the COX-2-PGE2-EP2 pathway, possi-
bly to alleviate progression of asthma. This effect
counterbalances HDM-induced damage by selectively
incrementing the interaction of PGE2 with its EP2 recep-
tor. The exogenous provision of PGE2 precludes endog-
enous counterparts from augmenting but helps sustain
high levels of EP2. This is the first report to characterize
the complete lung COX-2 pathway in vivo in a mouse
model of asthma including enzyme expression, PG pro-
duction, and PGE2 receptor expression. Given the com-
plexity of the multiple effects of PG, a time-course variable
needs to be incorporated into such studies to assess the
fluctuating activity of the endogenous COX-2 pathway in
HDM-sensitized mice, whether treated with PGE2 or not,
with the final aim of proposing potential targets for phar-
macological development.
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